Patient Medication Information: uses, side effects, how to take - Menveo
What is MENVEO used for?
MENVEO is a vaccine that is used to prevent a disease caused by groups A, C, W-135 and Y of the bacterium named Neisseria meningitidis. Neisseria meningitidis groups A, C; W-135 and Y bacteria can cause serious and sometimes life-threatening infections such as meningitis and sepsis (blood poisoning). This vaccine may be administered to individuals 2 months through 55 years of age.
This vaccine contains a protein (called CRM197) from the bacteria that cause diphtheria. MENVEO is not intended to protect against diphtheria. This means that you should receive other vaccines to protect against diphtheria when these are due or when advised by your doctor.
MENVEO cannot cause bacterial meningitis or diphtheria.
How does MENVEO work?
The vaccine works by causing your body to make its own protection (antibodies) against these bacteria. These antibodies fight the bacteria Neisseria meningitidis. If a vaccinated person comes into contact with N. meningitidis bacteria, the body is usually ready to destroy it.
The amount of time it takes for your body to develop enough antibodies to protect them against meningococcal diseases can vary. It can take several days to a few weeks after your vaccination.
The great majority of people who get vaccinated with MENVEO will produce enough antibodies to protect them against meningococcal disease. However, as with all vaccines, 100% protection cannot be guaranteed.
It is currently not known how long protection can last.
What are the ingredients in MENVEO?
Medicinal ingredients: Meningococcal group A, C, W-135 and Y oligosaccharide conjugated to Corynebacterium diphtheriae CRM197 protein.
MENVEO Powder and solution for injection (Lyophilized Powder/Liquid presentation):
Non-medicinal ingredients: Potassium dihydrogen phosphate, sodium chloride, sodium phosphate buffer (sodium dihydrogen phosphate monohydrate and di-sodium hydrogen phosphate dihydrate), sucrose, water for injection.
MENVEO (Liquid) Solution for injection (Liquid presentation):
Non-medicinal ingredients: Sodium chloride, sodium phosphate buffer (sodium dihydrogen phosphate monohydrate and di-sodium hydrogen phosphate dihydrate), water for injection.
MENVEO comes in the following dosage forms:
MENVEO is available as:
- powder and solution for injection; or,
- solution for injection
Each dose of MENVEO is supplied as a:
MENVEO Powder and solution for injection (Lyophilized Powder/Liquid presentation):
The contents of the two components are to be mixed prior to vaccination.
- 1 vial containing the MenA Lyophilised Conjugate Component as a white to off-white powder.
- 1 vial containing the MenCWY Liquid Conjugate Component as clear solution.
MENVEO (Liquid) Solution for injection (Liquid presentation):
- 1 vial containing MenACWY Liquid Conjugate Component as a clear solution.
Packaging:
The vial stopper does not contain dry natural rubber latex.
MENVEO Powder and solution for injection (Lyophilized Powder/Liquid presentation):
1 dose (2 vials) and/or 10 doses (20 vials).
MENVEO (Liquid) Solution for injection (Liquid presentation):
1 dose (1 vial) and/or 10 doses (10 vials).
Do not use MENVEO if:
MENVEO should not be given to persons that have:
- Ever had an allergic reaction to the active substance or any of the other ingredients of MENVEO.
- Ever had an allergic reaction to diphtheria toxoid (a substance used in a number of other vaccines).
- Ever shown any signs of allergy following vaccination with MENVEO.
MENVEO should not be administered to subjects with a known history of Guillain-Barré Syndrome.
To help avoid side effects and ensure proper use, talk to your healthcare professional before you take MENVEO. Talk about any health conditions or problems you may have, including if you:
Pregnancy and breast-feeding If you are pregnant, likely to become pregnant or are breast-feeding, you must tell your healthcare professional before MENVEO is given. Your healthcare professional may still recommend that you receive MENVEO if you are at high risk of infection with meningococcal group A, C; W-135 and Y bacteria. There is no data on fertility.
- Illness with high fever. The presence of a minor infection, such as a cold, should not require postponement of the vaccination, but talk to your healthcare professional first.
- Person with an allergy/hypersensitivity to any component of MENVEO, including CRM197 or other diphtheria-containing vaccines.
- Person who have diseases of the immune system or who are having treatment that affects the immune system. The vaccine may provide you with a lower level of protection than it does for people with healthy immune system. If possible, try to delay the vaccination after you complete the treatment that affects your immune system.
- If you receive treatment that blocks the part of the immune system known as complement activation, such as eculizumab. Even if you have been vaccinated with MENVEO you remain at increased risk of disease caused by the Neisseria meningitidis groups A, C, W-135 and Y bacteria.
- Person who have coagulation disorders or are on anticoagulant therapy. Tell the person giving you the injection of your condition. There is the risk of haemorrhage (excessive bleeding) if the injection is not done carefully.
Fainting, feeling faint or other stress-related reactions can occur as a response to any needle injection. Tell your healthcare professional if you have experienced this kind of reaction previously.
MENVEO can only protect against Neisseria meningitidis A, C, W-135 and Y serogroups and will not protect against disease caused by any other infectious agents.
Other warnings you should know about:
Driving and using machines
You may feel dizzy or experience some other side effects after the injection. These could interfere with your driving or operating machinery. Do not drive or operate machinery until you know how MENVEO affects you.
Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.
The following may interact with MENVEO:
MENVEO may be given at the same time as other vaccinations, but any other injected vaccines should preferably be given into a different limb from the site of the MENVEO injection. Separate injection sites must be used if more than one vaccine is being administered at the same time. These include: diphtheria toxoid, acellular pertussis, tetanus toxoid (DTaP) vaccine, Haemophilus influenza type b vaccine (Hib); inactivated polio vaccine, measles, mumps, rubella (MMR) and varicella vaccines, pentavalent rotavirus vaccine, 7-valent and 13-valent pneumococcal vaccine (PCV7 and PCV13), tetanus, reduced diphtheria and acellular pertussis vaccine (Tdap), and human papilloma virus vaccine (HPV).
MENVEO must not be mixed with other vaccines or medicinal products in the same syringe.
How to take MENVEO:
Usual dose:
Your healthcare professional will inject the recommended dose (0.5 mL) of the vaccine into your or your child’s arm or leg muscle.
Infants from 2 to 6 months of age
Three injections of MENVEO should be given with an interval of at least 2 months. The fourth injection should be administered during the second year of life (at 12-16 months).
Infants and toddlers from 7 to 23 months of age
Two injections of MENVEO, with the second injection administered in the second year of life and at least 2 months after the first injection.
Children above 2 years of age, adolescents and adults
One injection of MENVEO.
Overdose:
In case of vaccine overdose, contact a healthcare professional, hospital emergency department, or regional poison control centre immediately, even if there are no symptoms.
Missed Dose:
If you forget to go back to the healthcare professional at the scheduled time, ask the healthcare professional for advice.
What are possible side effects from using MENVEO?
These are not all the possible side effects you may have when taking MENVEO. If you experience any side effects not listed here, tell your healthcare professional.
Like all medicines, MENVEO can cause side effects, although not everybody gets them.
Children from 2 through 23 months of age
Very common (these may affect more than 1 in 10 people): change in eating habits, persistent crying, sleepiness, diarrhea, vomiting, irritability, tenderness at injection site, redness at injection site (≤ 50 mm), firmness at injection site (≤ 50 mm).
Common (these may affect up to 1 in 10 people): rash, tenderness at injection site, fever.
Uncommon (these may affect up to 1 in 100 people): redness at injection site (> 50 mm), firmness at injection site (> 50 mm).
Children from 2 through 10 years of age
Very common (these may affect more than 1 in 10 people): sleepiness, headache, irritability, generally feeling unwell, pain at injection site, redness at injection site (≤ 50 mm), firmness at injection site (≤ 50 mm).
Common (these may affect up to 1 in 10 people): change in eating habits, nausea, vomiting, diarrhea, rash, muscle pain, joint pain, chills, fever (≥38ºC), redness at injection site (>50mm), firmness at injection site (>50mm).
Uncommon (these may affect up to 1 in 100 people): itching at injection site.
Adolescents and adults
Very common (these may affect more than 1 in 10 people): headache, nausea, pain at injection site, redness at injection site (≤ 50 mm), firmness at injection site (≤ 50 mm), muscle pain, generally feeling unwell.
Common (these may affect up to 1 in 10 people): rash, redness at injection site (> 50 mm), firmness at injection site (> 50 mm), joint pain, fever (≥ 38°C), chills.
Uncommon (these may affect up to 1 in 100 people): dizziness, itching at injection site.
Side effects that have been reported during marketed use include (all age groups):
- Allergic reactions that may include severe swelling of the lips, mouth, throat (which may cause difficulty in swallowing), difficulty breathing with wheezing or coughing, rash and swelling of the hands, feet and ankles, loss of consciousness, very low blood pressure.
- Enlarged lymph nodes near injection site.
- Hearing impaired, ear pain, spinning sensation, dizziness, difficulties with balance, drooping of the upper eyelid, injection site itching, injection site pain, injection site redness, injection site inflammation, infection of the skin at the injection site, injection site swelling, including extensive swelling of the injected limb, tiredness, generally feeling unwell, fever, fall, head injury, increased liver function test result, body temperature increased, joint ache, bone pain, faint, fits (convulsions) including prolonged fits, fits associated with fever, headache, numbness and weakness of the face, sore throat, blistering of the skin called bullous conditions.
Tell your healthcare professional as soon as possible if you do not feel well after receiving MENVEO.
This is not a complete list of side effects. For any unexpected effects while taking MENVEO, contact your healthcare professional.
If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.
Reporting Suspected Side Effects for Vaccines
For the general public: Should you experience a side effect following immunization, please report it to your healthcare professional.
Should you require information related to the management of the side effect, please contact your healthcare professional. The Public Health Agency of Canada, Health Canada and GSK cannot provide medical advice.
For healthcare professionals: If a patient experiences a side effect following immunization, please complete the Adverse Events Following Immunization (AEFI) Form appropriate for your province/territory (http://www.phac-aspc.gc.ca/im/aefi-essi-form-eng.php) and send it to your local Health Unit.
Storage:
Store in a refrigerator at 2°C to 8°C. Do not freeze. Frozen/previously frozen product should not be used.
Protect from light. Do not use after expiration date.
Keep out of reach and sight of children.
If you want more information about MENVEO:
- Talk to your healthcare professional.
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website: (https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html); the manufacturer’s website www.gsk.ca, or by calling 1-800-387-7374.
Last Revised: November 21, 2025
©2025 GSK group of companies or its licensor
Trademarks are owned by or licensed to the GSK group of companies